Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine
Advanced Science · 2025
DOI: 10.1002/advs.202502937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yuan Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, T-Lymphocytes, Autoantigens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Tumor cells often down‐regulate antigen presentation and mount an immunosuppressive microenvironment, hindering successful cancer immunotherapy and vaccine development. Additionally, due to genomic instability, tumor cells are usually heterogeneous and constantly evolving. Therefore, vaccines need broad antigen coverage and rapid preparation. Here, a personalized whole tumor cell vaccine (TCV), termed fragment autoantigens stimulated T‐cell‐immunotherapy (FAST) is developed. In 7 h, tumor cells are treated with irradiation and cryoablation. Personalized fragmented antigens (FAs) from these treated cells are used as TCVs. In breast, colon, and melanoma mouse models, FAST achieved significant tumor regression, less metastasis, and longer survival. Notably, FAST outperforms other advanced TCVs, especially in curbing metastasis. Mechanistically, FAs activate efficient, broad‐spectrum antigen presentation due to upregulation of immunogenic cell death, MHC‐I, and damage‐associated molecular patterns. Concurrently, FAST also enhances anti‐tumor immunity by reshaping immune microenvironments. Analysis of clinical data shows FAST‐associated proteins have prognostic and therapeutic value in patients with liver, stomach, rectal cancers, and melanoma. These results suggest FAST has high anti‐tumor efficacy and potential as a personalized TCV platform. The relevant clinical trial NCT06756295 is under initiation with approval of ethics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Nuclear Physics and Technology, School of Physics, Peking University, Beijing, 100871, China.
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 352001, China.
- Department of Physics, Princeton University, Princeton, NJ, 08544, USA.
- Center for Quantitative Biology, Peking University, Beijing, 100871, China.
- Department of Clinical Oncology, University of Hong Kong, Hong Kong, 999077, China.
ORCID-Profile: Gen Yang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shenzhen Science and Technology Program
Zitieren
APA
Li, Y., Chen, H., Shen, Q., Liu, Y., Li, P., Ma, Y., Wang, Y., Li, S., Yan, X., Liu, L., Shuai, J., Wu, M., Ouyang, Q., Kong, F. S., & Yang, G. (2025). Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine. Advanced Science. https://doi.org/10.1002/advs.202502937
Vancouver
Li Y, Chen H, Shen Q, Liu Y, Li P, Ma Y, et al. Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine. Advanced Science. 2025. doi:10.1002/advs.202502937
BibTeX
@article{Li2025,
author = {Li, Yuan and Chen, Huiqin and Shen, Qiaofeng and Liu, Yingshuang and Li, Pingping and Ma, Yuqi and Wang, Yugang and Li, Shengkai and Yan, Xueqing and Liu, Liyu and Shuai, Jianwei and Wu, Min and Ouyang, Qi and Kong, Feng-Ming Spring and Yang, Gen},
title = {Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502937}
}
EUVIMED